Analyst Actions -- 9/20/2011

 | Sep 20, 2011 | 2:19 PM EDT  | Comments
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

abt

,

jpm

,

mrvl

,

mcp

,

pru

,

fdx

,

mu

,

nok

,

bbby

,

x

,

aapl

Abbott Laboratories rated new Buy at Jefferies

Coverage of ABT was started with a Buy rating, Jefferies said. $60 price target. Fears of Humira competition are overdone.

----- 

Adobe Systems numbers lowered at ThinkEquity

Shares of ADBE now seen reaching $27, according to ThinkEquity. Estimates also cut, given slower growth in Europe. Hold rating.

-----

Apple added to Best Ideas List at Wedbush

AAPL was placed on the Best Ideas list, Wedbush Securities said. New $530 price target. Company should continue to see solid demand for the iPhone and iPad.

-----

Bed Bath & Beyond estimates, target raised at UBS

Shares of BBBY now seen reaching $62, according to UBS.  Estimates also increased on expected solid 2Q11 results.  Neutral rating.

-----

CBOE estimates, target boosted at Jefferies

Shares of CBOE now seen reaching $27, according to Jefferies. Estimates also upped, given higher expected volume growth. Hold rating.

-----

Coventry Health downgraded at Wedbush

CVH was downgraded from Neutral to Underperform, Wedbush said. $32 price target. Pricing cycle may be turning for the worse.

-----

FedEx estimates, target cut at Citigroup

Shares of FDX now seen reaching $95, according to Citigroup.  Estimates also lowered as data points to slower growth.  Buy rating.

-----

FedEx estimates, target lowered at Dahlman Rose

FDX estimates were cut through 2013, Dahlman Rose said. Company is leveraged to slower economic growth. Buy rating and new $120 price target.  

-----

Hub Group estimates, target lowered at UBS

Shares of HUBG now seen reaching $32.50, according to UBS.  Estimates also lowered on higher macro risk.  Neutral rating.

-----

Intercontinental Exchange estimates upped at Jefferies

ICE estimates were boosted through 2012, Jefferies said. Trading activity is improving. Buy rating and $145 price target.

-----

JPMorgan Chase rated new Overweight at Evercore

JPM was initiated with an Overweight rating, Evercore Partners said. $46 price target. Company can continue to gain market share.

-----

Lennar estimates lowered at Citigroup

LEN estimates lowered through 2012, Citigroup said.  Macro risks and aggressive use of balance sheet.  Maintain Hold rating.

----- 

Marvell Technology downgraded at JMP

MRVL was downgraded to Market Perform, JMP Securities said. Estimates also cut, as the company is facing potential growth headwinds.

-----

MGM Resorts upgraded at Morgan Stanley

MGM was upgraded from Equal-weight to Overweight, Morgan Stanley said. $15 price target. Company is leveraged to improving leisure trends in Las Vegas.

-----

Micron Technology estimates lowered at Sterne Agee

MU estimates were cut through 2013, Sterne Agee said. Company is leveraged to lower DRAM pricing. Buy rating and $14 price target.

-----

Molycorp downgraded at JP Morgan

MCP was downgraded to Neutral, JP Morgan said. Estimates also cut, given uncertain pricing and demand. $66 price target.

-----

Moody's downgraded at Benchmark

MCO was downgraded from Buy to Hold, Benchmark said. $29 price target. Company will be hurt by the turbulent market environment.

-----

Mosaic upgraded at CIBC

MOS was upgraded to Sector Outperform, CIBC said. Company is leveraged to higher potash prices. $88 price target.

-----

Nasdaq OMX estimates increased at Jefferies

NDAQ estimates were raised through 2012, Jefferies said. Volumes trends are improving. Hold rating and $27 price target.

-----

Nokia estimates, target reduced at Wedbush

Shares of NOK now seen reaching $6, according to Wedbush. Estimates also cut, as the company is losing market share. Neutral rating.

-----

Progress Energy rated new Outperform at BMO

PGN was initiated with an Outperform rating, BMO Capital said. $18 price target. Company has a significant resource base and deserves a premium valuation.

-----

Prudential target cut at FBR

Shares of PRU now seen reaching $66, according to FBR Capital Markets. Company is being hurt by lower interest rates. Outperform rating.

-----

PSS World Medical numbers reduced at Credit Suisse

Shares of PSSI  now seen reaching $27, according to Credit Suisse. Estimates also cut, given lower utilization rates. Outperform rating.

-----

Pulte Homes upgraded at UBS

PHM was upgraded from Neutral to Buy, UBS said.  $8 price target.  Opportunities arise as new home market bottoms.

-----

Salix Pharmaceutical estimates, target cut at UBS

Shares of SLXP now seen reaching $32, according to UBS.  Estimates also lowered to reflect higher equity and fundamental risk.  Neutral rating.

-----

Tempur-Pedic rated new Neutral at Goldman

TPX was initiated with a Neutral rating, Goldman Sachs said. Valuation call, based on a $66 price target.

-----

US Steel numbers reduced at Keybanc

Shares of X now seen reaching $45, according to Keybanc. Estimates also cut, given slower growth in Europe. Buy rating.

Columnist Conversations

Lockheed Martin is fading into the close. The stock opened the session with a gap higher open after rep...
It's hard to argue with the price action or the momentum indicators, but volume, as reflected on the graph at ...
Time resistance to the current rally comes in between 4/22-24. Good reason to trail up stops on any longs! ...
Market continues to power higher going into the last hour of trading. Looking forward to earnings after the b...

BEST IDEAS

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.